NORDIC | BIOTECH & HEALTHCARE Your insights into listed Danish & Nordic biotech & healthcare stocks.
In the past week, the Nordic biotech and healthcare stocks declined slightly by 0.7%, with the Danish ones falling 6.6% as DanCann Pharma lost two-thirds of its market cap. During the week, Biosergen raised MSEK 44.9, while ExpreS2ion raised MSEK 10, and received approval to initiate a phase I study for a vaccine candidate against HER2-expressing breast cancer. Finally, JP Morgan cut its price target for Genmab from DKK 2,050 to DKK 1,700, but the target is still higher than the current share price of DKK 1,546.
8 of the 22 Danish biotech companies had a positive share price development in the past week and 13 companies have had a positive share price performance year-to-date. Obesity continues to drive the best performances with Gubra, Zealand Pharma, and Pila Pharma having strong YTD performance. 5 Danish healthcare stocks with +100% YTD return.
Danish company news
No news in the past week
No news in the past week
Biosergen AB receives approximately SEK 44.9 million through warrants of series TO3 (Link)
Biosergen resolves on a compensation issue to underwriters in connection with the completed exercise period for warrants of series TO3 (Link)
No news in the past week
No news in the past week
Curasight will announce the outcome of the exercise of its warrants of series TO2 today with the results yet to be announced by the company.
No news in the past week
Evaxion to present preclinical Proof-of-Concept for precision ERV cancer vaccine concept at ESMO Immuno-Oncology Congress (Link)
ExpreS2ion announces approval to initiate a Phase I clinical trial of ES2B-C001, its novel therapeutic vaccine, being developed for HER2-expressing breast cancer (Link)
Warrants of series TO 10 were exercised to approximately 69 percent and ExpreS2ion receives approximately SEK 10 million (Link)
No news the past week
JP Morgan cut its price target from DKK 2,050 to DKK 1,700.
No news the past week
No news the past week
No news the past week
No news the past week
No news the past week
No news the past week
No news the past week
No news the past week
No news the past week
No news the past week
No news the past week
Share price development – Danish stocks
On average, Danish biotech and healthcare stocks delivered a negative return of 6.6% after two weeks in a row with double-digit returns. There was notably little to no news in the past week, where many companies seemed to decline following low traded volume. Biosergen, however, raised MSEK 44.9, while ExpreS2ion received MSEK 10, and got approval to initiate a phase 1 study for a vaccine candidate against HER2-expressing breast cancer. Finally, JP Morgan cut its price target Genmab from DKK 2,050 to DKK 1,700, but it is still higher than the current share price of DKK 1,546. Two-thirds of the market value in DanCann Pharma was lost during the week without any news.
Gubra continues to be the best-performing stock year-to-date with a return of 460%. Pila Pharma, Saniona, Zealand Pharma and ViroGates have also generated more than a 100% return.
Overview of share price development the past week, year-to-date, and the last twelve month
Nordic Biotech & Healthcare Developments
The Kapital Partner Nordic Healthcare Index (KPHC) decreased by 0.7% to 64,01 in the past week. After a good start to the year, the index declined together with the other indexes from July to November, and now the indexes seem to be at a turning point testing higher grounds. The 1-year return for the KPHC index has almost been erased by the past months of poor performance.
The Nordic healthcare stocks (KPHC) vs. C25, S30, and KPNGX the past year
The top three best-performing stocks in the past week
Alteco Medical (99%) offers a medical device for extracorporeal blood purification. The product removes endotoxin (lipopolysaccharide, LPS) from the patient’s bloodstream, and is applied as an add-on therapy in sepsis to treat endotoxemia (high levels of endotoxin). This can help stabilize the patient in acute situations. Endotoxemia is often present in sepsis, a life-threatening condition and one of the most common causes of death in modern intensive care. The stock rose following a distribution agreement with Medica S.p.A with exclusive rights to commercialize Alteco LPS adsorber in Italy, Germany, UK, France, Spain, and Switzerland running for 3 years.
Eevia Health (61%) is a life science company. The company offers production protocols and procedures for delivering organic products to international customers. The products are sold to corporate customers and include ingredients for manufacturers of dietary supplements, food, and cosmetics on a global basis. The products include, for example, blueberries, chaga mushrooms, and pine bark.
Infant Bacterial Therapeutics (60%) is a pharmaceutical company. The company develops drugs to treat and prevent children from developing common ailments and diseases that occur at premature birth. Common is that disorders can occur in the development of microorganisms such as microbiome. The largest operations are in the Nordic market.
Resources: Refinitiv Eikon, Cision, Nordnet & company websites
